FDA: Turkish OTC drug maker Cerci shipped to the U.S. without finished-product identity and strength testing.
What happened
FDA did not inspect the plant; it reviewed records the company submitted in response to requests dated June 16, 2022 and July 6, 2023 under section 704(a)(4) of the FD&C Act, which lets FDA demand records instead of visiting. The records showed the company released an OTC drug to the U.S. without testing each batch for identity and strength of the active ingredient, lacked stability data to support its 24-month expiry (no impurity or microbiological testing), and gave no evidence it tests incoming active ingredient lots for identity. FDA placed the firm on Import Alert 66-40 on October 27, 2023.
What FDA found
The company released batches of its OTC drug for the U.S. without laboratory testing to confirm the identity and strength of the active ingredient.
21 CFR 211.165(a)Its stability program was inadequate: it did not show the product stays within specifications through the 24-month expiry and did not test for impurities or microorganisms.
21 CFR 211.166(a)The company said it tests each incoming lot of active ingredient for identity, but provided no test results to prove it.
21 CFR 211.84(d)(1) and (d)(2)
What FDA wants
FDA tells the company to correct the violations promptly and reply in writing within 15 working days with what it has done, including test methods, a plan and results for testing retained samples of U.S. batches still within expiry, an independent review of its laboratory, a stability program corrective plan, and evidence of active ingredient identity testing. FDA also recommends hiring a qualified CGMP consultant before resuming manufacturing for the U.S. market.
Who should pay attention
- U.S. distributors and retailers that stock imported OTC drug products
- brands relying on foreign manufacturers' certificates of analysis for release
- companies buying OTC drugs from Turkish contract manufacturers
This is a summary. Read the original letter on fda.gov.